A Vaccines Renaissance, Spurred By COVID-19, Is Underway
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.
You may also be interested in...
GSK Has Big Ambitions In Vaccines, With An Eye On Blockbuster Opportunities
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
With Prevnar 20, Pfizer Aims To Maintain A Top Franchise
The successor to Pfizer’s 13-valent pneumococcal vaccine, a lynchpin of the company's lifecycle management strategy, was approved in the US.
Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected
Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.